Pelthos Therapeutics Inc. Retained Earnings
Pelthos Therapeutics Inc. (PTHS) had Retained Earnings of -$113.28 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$113.28M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$89.87M; Retained Earnings (Accumulated Deficit) as first filed -$75.03M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$64.79M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$43.13M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$113.28M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$89.87M 10-Q/A · filed 2026-08-13 | -$75.03M 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$64.79M 10-Q/A · filed 2026-08-13 | |
| 2025-09-30 | -$43.13M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$26.89M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$23.44M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$21.48M 10-K · filed 2026-03-19 | -$21.47M 10-K · filed 2025-03-27 |
| 2024-09-30 | -$19.55M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$17.85M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$16.08M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$13.52M 10-K · filed 2025-03-27 | |
| 2022-12-31 | -$6.14M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |